Skip to content

Technique refinement and clinical popularization of abdominal aortic balloon occlusion

Study on technical optimization and clinical application of abdominal aortic balloon

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056882
Enrollment
Unknown
Registered
2022-02-22
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic tumors, sacral tumor

Interventions

Group 1:Partial abdominal aortic balloon occlusion
Group 2:Complete abdominal aortic balloon occlusion

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Sacral and pelvic tumors, such as chordoma, chondrosarcoma, giant cell tumor of bone, Ewing's sarcoma, osteosarcoma or other malignant tumors, according to preoperative examination, the tumor has abundant blood supply, and the intraoperative bleeding is expected to be large; 2. Aged 18-70, no gender limit; 3. Patients who have no contraindications for abdominal aortic balloon operation and need abdominal aortic balloon implantation; 4. Expected life expectancy is more than 1 year; 5. Good compliance, and can cooperate with the whole treatment, evaluation and follow-up.

Exclusion criteria

Exclusion criteria: 1. Combined with other malignant tumors; 2. Uncontrolled hypertension (systolic blood pressure >=140mmHg or diastolic blood pressure >=90mmHg, despite optimal medical therapy); 3. Patients with NYHA grade III-IV cardiac insufficiency, or left ventricular ejection fraction < 50% by cardiac color Doppler ultrasonography, myocardial infarction within 6 months before enrollment, New York Heart Association grade ? or above heart failure, controlled angina, clinically significant pericardial disease, or electrocardiogram indicating acute ischemia or abnormal active conduction system; 4. History of thrombosis/tumor thrombus in the lower extremity or pelvic cavity, blood supply disorders in the lower extremity or pelvis, and vascular malformations in the lower extremity or pelvic cavity; 5. Patients with a history of psychotropic drug abuse and unable to abstain or with mental disorders; 6. Any condition that, in the opinion of the Investigator, may harm the subject or prevent the Subject from meeting or performing the study requirements.

Design outcomes

Primary

MeasureTime frame
Intraoperative blood loss;Time of occlusion;

Countries

China

Contacts

Public ContactYan Taiqiang

Peking University People's Hospital

yantqzh@163.com+86 13910733583

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026